

Amendments to the Specification

Please replace paragraph [0013] with the following paragraph:

In some embodiments, the antibody or antigen-binding fragment thereof binds to an polypeptide bound by a monoclonal antibody produced by a hybridoma selected from the group consisting of: HB 7E11 (ATCC® accession No. PTA-4587), HB 1H2 (ATCC® accession No. PTA-4584), HB 3G5 (ATCC® accession No. PTA-4586), HB 5B10 (ATCC® accession No. PTA-4588) and HB 2F7 (ATCC® accession No. PTA-4585). In some embodiments, the monoclonal antibody is produced by the HB 7E11 hybridoma. In some embodiments, the polypeptide comprises an amino acid sequence selected from the group consisting of: AAAFTGLTLLEQLDLSDNAQLR (SEQ ID NO: 7); LDLSDNAQLR (SEQ ID NO: 8); LDLSDDAELR (SEQ ID NO: 9); LDLASDNAQLR (SEQ ID NO: 10); LDLASDDAELR (SEQ ID NO: 11); LDALSDNAQLR (SEQ ID NO: 12); LDALSDDAELR (SEQ ID NO: 13); LDLSSDNAQLR (SEQ ID NO: 14); LDLSSDEAELR (SEQ ID NO: 15); DNAQLRVVDPTT (SEQ ID NO: 16); DNAQLR (SEQ ID NO: 17); ADLSDNAQLRVVDPTT (SEQ ID NO: 18); LALSDNAQLRVVDPTT (SEQ ID NO: 19); LDLSDNAALRVVDPTT (SEQ ID NO: 20); LDLSDNAQLHVVDPTT (SEQ ID NO: 21); and LDLSDNAQLAVVDPTT (SEQ ID NO: 22).

Please replace the Sequence Listing at the end of the specification with the Substitute Sequence Listing filed herewith.